Enhanced dissolution and oral bioavailability of piroxicam formulations: Modulating effect of phospholipids

Pharmaceutics

Volumn 2, Issue 4, 2010, Pages 339-350

  Mirza, Sabiruddin ^a   Miroshnyk, Inna ^a   Habib, Muhammad J ^b   Brausch, James F ^c   Hussain, Muhammad D ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HOWARD UNIVERSITY   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Bioavailability; Dissolution; Phospholipids; Poorly water soluble drugs; Solid dispersions

Indexed keywords

DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; PHOSPHOLIPID; PIROXICAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SOLID STATE; THERMODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79952123586     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics2040339     Document Type: Article

References (31)

1. Amidon, G.L.; Lennernas, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
2. Serajuddin, A.T.M. Salt formation to improve solubility. Advan. Drug Delivery Rev. 2007, 59, 603-616.
3. Merisko-Liversidge, E.; Liversidge, G.G.; Cooper, E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18, 113-120.
4. Chiou, W.; Riegelman, S. Pharmaceutical applications of solid dispersion system. J. Pharm. Sci. 1971, 60, 1281-1302.
5. Serajuddin, A.T.M. Solid dispersion of poorly water soluble drugs, early promises, subsequent problems and recent breakthroughs. J. Pharm. Sci. 1999, 88, 1058-1066.
6. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50, 47-60.
7. Copland, M.J.; Rades, T.; Davies, N.M.; Baird, M.A. Lipid based particulate formulations for the delivery of antigen. Immunol. Cell Biol. 2005, 83, 97-105.
8. Marsac, P.J.; Li, T.; Taylor, L.S. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm. Res. 2009, 26, 139-151.
9. Shikov, A.N.; Pozharitskaya, O.N.; Miroshnyk, I.; Mirza, S.; Urakova, I.N.; Hirsjärvi, S.; Makarov, V.G.; Heinämäki, J.; Yliruusi, J.; Hiltunen, R. Nanodispersions of taxifolin: impact of solid-state properties on dissolution behavior. Int. J. Pharm. 2009, 377, 148-152.
10. Fini, A.; Cavallari, C.; Ceschel, G.; Rabasco, A.M. Bimodal release of olanzapine from lipid microspheres. J. Pharm. Sci. 2010, 99, 4251-4260.
11. Craig, D.Q.M. The mechanisms of drug release from solid dispersions in water soluble polymers. Int. J. Pharm. 2002, 231, 131-144.
12. Forster, A.; Rades, T.; Hempenstall, J. Selection of suitable drug and excipient candidates to prepare glass solutions by melt extrusion for immediate release oral formulations. Pharm. Tech. Eur. 2002, 14, 27-37.
13. Biswas, M.; Akogyeram, C.O.; Scott, K.R.; Potti, G.K.; Gallelli, J.F.; Habib, M.J. Development of carbamazepine:phospholipid solid dispersion formulations. J. Control. Release 1993, 23, 239-245.
14. Potti, G.; Gallelli, J.; Akoggeram, C.; Ahmadi, B.; Habib, M. Improved dissolution of indomethacin in coprecipitates with phospholipids - II. Drug Dev. Ind. Pharm. 1993, 19, 1221-1229.
15. Yamamura, S.; Rogers, J.A. Characterization and dissolution behavior of nifedipine and phosphatidylcholine binary systems. Int. J. Pharm. 1996, 130, 65-73.
16. Venkataram, S., Rogers, J. Characteristics of drug-phospholipid coprecipitates I: Physical properties and dissolution behavior of griseofulvin-dimyristoylphosphatidylcholine systems. J. Pharm. Sci. 1984, 73, 757-761.
17. Lichenberger, L.; Wang, Z.-M.; Romero, J.; Ulloa, C.; Perez, J.; Giraud, M.N.; Barreto, J. Nonsteroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat. Med. 1995, 1, 154-158.
18. Budavari, S. The Merck Index, 12th ed.; Merck & Co., Inc.: Whitehouse Station, NJ, USA, 1996; p. 839.
19. Tantishaiyakul, V.; Kaewnopparat, N.; Ingkatawornwong, S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30. Int. J. Pharm. 1996, 143, 59-66.
20. Pan, R.N.; Chen, J.H.; Chen, R.R. Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems. Drug Dev. Ind. Pharm. 2000, 26, 989-994.
21. Wu, K.; Li, J.; Wang, W.; Winstead, D.A. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J. Pharm. Sci. 2009, 98, 2422-2431.
22. Prabhu, S.; Ortega, M.; Ma, C. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water -soluble model drug, piroxicam. Int. J. Pharm. 2005, 301, 209-216.
23. Rocci, M.L.; Jusko, W.J. Lagran program for area and moments in pharmacokinetic analysis. Comput. Progr. Biomed. 1983, 16, 203-216.
24. Boudinot, F.D.; Ibrahim, S.S. High-performance liquid chromatographic assay for piroxicam in human plasma. J. Chromatogr. 1998, 430, 424-428.
25. Lingyun, Z.; Feng, S.S. Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes. J. Colloid Interface Sci. 2004, 274, 55-68.
26. Riske, K.A.; Döbereiner, H.-G.; Lamy-Freund, M.T. Gel-Fluid Transition in Dilute versus Concentrated DMPG Aqueous Dispersions. J. Phys. Chem. B 2002, 106, 239-246.
27. Vrecer, F.; Vrbink, M.; Meden, A. Characterization of piroxicam crystal modifications. Int. J. Pharm. 2003, 256, 3-15.
28. Sheth, A.R.; Bates, S.; Muller, F.X.; Grant, D.J.W. Local structure in amorphous phases of piroxicam from powder x-ray diffractometry. Cryst. Growth Des. 2005, 5, 571-578.
29. Kojic-Prodic, B.; Ruzic-Toros, Z. Structure of the anti-inflammatory drug 4-hydroxy-2-methyl-N-2-pyridyl-2H-1λ6,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam). Acta Crystallogr. Sect. B 1982, 38, 2948-2951.
30. Reck, G.; Dietz, G.; Laban, G.; Gunther, W.; Bannier, G.; Hohne, E. X-ray studies on piroxicam modifications. Pharmazie 1988, 43, 477-481.
31. Lee, C.R.; Balfour, J.A. Piroxicam-β-cyclodextrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states. Drugs 1994, 48, 907-929.